Clinical review report: Fluocinolone acetonide intravitreal implant (Iluvien) (Knight therapeutics inc.)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of an fluocinolone acetonide 0.2 mcg/day intravitreal implant for patients with diabetic macular edema
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2019, 2019
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of an fluocinolone acetonide 0.2 mcg/day intravitreal implant for patients with diabetic macular edema |
|---|---|
| Item Description: | "Indication: For the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.". - "Final (with redactions)" |
| Physical Description: | 1 PDF file (108 pages) illustrations |